Have to disagree entirely. If Oncarlytics is so outstanding as to render the b-cell platform redundant, then IMU will be swimming in cash to the point it won't make much difference if they sold it or not.
If Oncarlytics turns out to be anything less than exceptional, then there is still a huge amount to be gained from progressing b-cell and it leaves the company with plenty of options. Not to mention that any sale would likely be well under value at this stage.
Have to disagree entirely. If Oncarlytics is so outstanding as...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $556.3M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 143589 | 8.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 17400 | 1 |
View Market Depth
| Last trade - 09.56am 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
0.000 ( 1.32 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.7¢ | 7.5¢ | 1102850 | ||
| Last updated 10.14am 08/05/2024 ? | |||||
| IMU (ASX) Chart |
Day chart unavailable